• Explore /
  • Poster
  • / Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

Abstract Video & Slides Poster

Authors

null

Do-Youn Oh

Seoul National University Hospital, Seoul, South Korea

Do-Youn Oh , Kyung-Hun Lee , Dae-Won Lee , Tae Yong Kim , Ju-Hee Bang , Ah-Rong Nam , Young Lee , Qu Zhang , Marlon Rebelatto , Weimin Li , Jin Won Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03046862

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4520)

DOI

10.1200/JCO.2020.38.15_suppl.4520

Abstract #

4520

Poster Bd #

128

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Jin Won Kim

First Author: Jia Fan

First Author: Richard D. Kim